Form 4: GYRE Therapeutics President Sells Over 2,500 Shares Under Pre-Arranged Trading Plan

Ma Songjiang, President and Director of GYRE Therapeutics, Inc., has reported the sale of 2,558 shares of common stock in late May 2025, executed under a pre-established Rule 10b5-1 trading plan.

Summary

• Ma Songjiang, who serves as President, Director, and a 10% Owner of GYRE Therapeutics, Inc. (GYRE), reported two transactions involving the sale of common stock.
• On May 27, 2025, Mr. Ma sold 2,000 shares of GYRE common stock at a weighted average price of $10.28 per share, with prices ranging from $10.00 to $11.44.
• On May 28, 2025, an additional 558 shares were sold at a weighted average price of $10.07 per share, with prices ranging from $10.00 to $10.29.
• Both transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these sales, Mr. Ma's beneficial ownership of common stock stands at 2,806,084 shares, held indirectly by his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that these sales were conducted under a pre-arranged Rule 10b5-1 trading plan mitigates any immediate negative implications, as it indicates a planned, non-discretionary transaction.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by investors as it may suggest a lack of confidence in the company's future prospects, although this is mitigated by the 10b5-1 plan.

Risks

• The sale of shares by a key executive and director could potentially lead to negative investor sentiment, impacting the stock price, although the pre-arranged nature of the sale under a 10b5-1 plan typically lessens this impact.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024, indicating a pre-scheduled sale rather than a discretionary one based on immediate market conditions.

Industry Context

This filing is specific to an insider transaction at GYRE Therapeutics and does not provide broader industry trends or context. Insider sales are a routine part of executive compensation and personal financial planning across all industries.

Stakeholder Impact

• Shareholders: May observe the insider selling as a data point for their investment decisions, though the 10b5-1 plan context is important for interpretation.

Next Steps

• The reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the Issuer, or a security holder of the Issuer.

Key Dates

Keywords

GYRE Therapeutics, GYRE, Ma Songjiang, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Corporate Governance